Matinas Biopharma (NYSEAMERICAN:MTNB) Trading Down 3.7% – Time to Sell?

Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB)’s share price dropped 3.7% during mid-day trading on Monday . The stock traded as low as $0.5265 and last traded at $0.54. Approximately 41,451 shares were traded during trading, an increase of 23% from the average daily volume of 33,766 shares. The stock had previously closed at $0.5610.

Matinas Biopharma Trading Down 3.7%

The stock has a market capitalization of $3.46 million, a PE ratio of -0.27 and a beta of 1.61. The firm has a 50-day moving average price of $0.58 and a 200-day moving average price of $0.70.

Matinas Biopharma (NYSEAMERICAN:MTNB) last announced its earnings results on Friday, May 8th. The company reported ($0.30) earnings per share (EPS) for the quarter.

Institutional Investors Weigh In On Matinas Biopharma

A hedge fund recently bought a new stake in Matinas Biopharma stock. DRW Securities LLC bought a new stake in shares of Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 46,374 shares of the company’s stock, valued at approximately $27,000. DRW Securities LLC owned about 0.72% of Matinas Biopharma at the end of the most recent reporting period. Hedge funds and other institutional investors own 11.77% of the company’s stock.

About Matinas Biopharma

Matinas Biopharma Inc is a clinical‐stage biopharmaceutical company that specializes in the development of novel lipid‐based drug delivery platforms. Its proprietary Lipid NanoSphere (LNS) technology is designed to encapsulate water‐soluble and hydrophobic therapeutic agents, enabling both oral and intravenous administration. The company’s approach aims to improve drug pharmacokinetics, enhance bioavailability and reduce systemic toxicity compared with conventional formulations.

The lead product candidate, MAT2203, is an oral formulation of amphotericin B being developed for the treatment of cryptococcal meningitis and other life‐threatening fungal infections.